Skip to content
About Us
Pipeline
Publications
Investor Relations
Contact Us
×
About Us
Pipeline
Publications
Investor Relations
Contact Us
Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
Scroll To Top